EDITORIAL · RESEARCH OF RECORD
About TB-500 Source
What this project is, what "source" means here, and the line we hold between summarizing research and supplying anything.
What TB-500 Source is
TB-500 Source keeps a reconciliation ledger over the published research on Thymosin Beta-4 and its Ac-LKKTETQ fragment: it takes the claims that circulate about this peptide and traces each one upstream to its headwaters in the primary literature, reconciling what is said against what was actually shown. It is a ledger to read, not a place to buy from. The word 'source' names that tracing work — following claims to their origin — and not a supply relationship. Nothing here is sold, supplied, sourced for purchase, or dosed; no prescription is filled, no visit booked, no clinician kept, and no medical direction given.
What "source" means on this site
'Source' on this site means the origin of a claim — the study or document it can be traced to — not a place to source the compound. There is no supplier here, no stock, and no purchase path, and the name should not be read as an offer to provide the peptide. What the ledger reconciles is the evidence: where a claim matches its source, where it drifts from it, and where no primary source can be found at all. That is stated plainly so 'source' is never mistaken for a storefront.
How we handle evidence and its limits
Every entry in the ledger is reconciled to a source. A quantitative claim is recorded only against a specific peer-reviewed study, registered trial, or regulatory document, and each reference is checkable. Failed replications and negative results are entered beside the favorable ones, and vendor copy that treats the synthetic fragment as full-length Tβ4 is corrected against the structural record. Where the evidence simply runs out, the ledger says so rather than filling the gap. No seller is linked; it points outward only to PubMed, ClinicalTrials.gov, the NIH, journals, and the agencies.